Stockreport

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate [Seeking Alpha]

Nuvation Bio Inc. Class A  (NUVB) 
PDF Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also n [Read more]